Aveo Pharmaceuticals (AVEO) 0.94 $AVEO 7 Biotech Stocks

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Aveo Pharmaceuticals (AVEO) 0.94 $AVEO

7 Biotech Stocks that are Buys Right Now
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 10:00AM CDT
Buy these seven biotech stocks now and see how well the second half of 2016 unfolds for this industry.
MSTX: 0.45 (unch), RTRX: 18.39 (-0.09), AVEO: 0.94 (-0.05), SNSS: 0.56 (unch), LGND: 114.20 (+0.37), BIND: 0.40 (-0.01), ACOR: 25.73 (+0.46)

AVEO to Present at the 2016 JMP Securities Life Science Conference
BusinessWire - Wed Jun 15, 6:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced that Michael Needle, M.D., Chief Medical Officer, will present at the 2016 JMP Securities Life Sciences Conference on Wednesday, June 22, 2016 at 11:00 AM Eastern Time. The conference is being held at the St. Regis Hotel in New York.
AVEO: 0.94 (-0.05)

Will AVEO Pharmaceuticals (AVEO) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 4:52AM CDT
As of late, it has definitely been a great time to be an investor AVEO Pharmaceuticals, Inc. (AVEO)
AVEO: 0.94 (-0.05)

AVEO Announces Dosing of First Patient in the Pivotal Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma
BusinessWire - Thu May 26, 6:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced that the first patient has been dosed in the Company's pivotal TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC). Tivozanib is an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI).
AVEO: 0.94 (-0.05)

AVEO Announces Closing of Private Placement and Amended Term Loan to Fund Pivotal TIVO-3 Trial and Combination PD-1 Trial of Tivozanib in Renal Cell Cancer
BusinessWire - Wed May 18, 6:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced that it has closed its previously announced private placement of 17,642,482 units, consisting of one share of common stock and a warrant to purchase one share of common stock, at a price of $0.965 per unit, for gross proceeds of approximately $17 million. The transaction was led by New Enterprise Associates and included New Leaf Venture Partners and Perceptive Advisors, among other institutional investors. Certain members of the Company's management team and Board of Directors also participated in the financing.
AVEO: 0.94 (-0.05)

AVEO Announces $17 Million Private Placement
BusinessWire - Fri May 13, 8:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced that it entered into a securities purchase agreement for a private placement with a select group of qualified institutional buyers, institutional accredited investors and accredited investors. The private placement will consist of 17,642,482 units, at a price of $0.965 per unit, for gross proceeds of approximately $17 million, before deducting placement agent fees and estimated offering expenses. Each unit consists of one share of AVEO's common stock and a warrant to purchase one share of AVEO's common stock. The warrants will have an exercise price of $1.00 per share and will be exercisable for a period of five years from the date of issuance. The closing of the financing is expected to take place on or about May 18, 2016, and is subject to standard closing conditions. AVEO expects to use the proceeds from the financing to fund its U.S. pivotal Phase 3 trial of tivozanib, to support a combination trial of tivozanib with a PD-1 inhibitor and for general corporate purposes.
AVEO: 0.94 (-0.05)

AVEO Q1 Loss In Line with Expectation, Tivozanib in Focus
Zacks Equity Research - Zacks Investment Research - Wed May 11, 9:19AM CDT
AVEO Pharmaceuticals' (AVEO) first-quarter 2016 loss of 13 cents per share came in line with the Zacks Consensus Estimate.
ANIP: 55.29 (+2.50), RTRX: 18.39 (-0.09), AVEO: 0.94 (-0.05), BMY: 72.34 (+0.03)

AVEO reports 1Q loss
Automated Insights - Tue May 10, 3:13PM CDT
CAMBRIDGE, Mass. (AP) _ AVEO Pharmaceuticals Inc. (AVEO) on Tuesday reported a loss of $7.7 million in its first quarter.
AVEO: 0.94 (-0.05)

AVEO Oncology Reports First Quarter 2016 Financial Results and Provides Business Update
BusinessWire - Tue May 10, 3:01PM CDT
AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2016.
AVEO: 0.94 (-0.05)

Drug Stocks Earnings Preview: GERN, RPRX, ICPT, AGIO & More
Zacks Equity Research - Zacks Investment Research - Wed May 04, 10:25AM CDT
As we approach the end of this earnings season, investors will possibly heave a sigh of relief seeing that the going was not as bad as expected.
ABT: 39.05 (+0.31), BIIB: 237.34 (+2.74), CNAT: 2.09 (+0.05), AMGN: 151.06 (+1.25), RPRX: 1.64 (+0.01), JNJ: 117.06 (+0.60), GILD: 83.17 (+0.72), GWPH: 88.76 (+0.19), GERN: 2.69 (+0.02), AVEO: 0.94 (-0.05), ICPT: 149.32 (+1.22), AGIO: 47.95 (+0.88), NVS: 80.21 (+0.50)

Will AVEO Pharmaceuticals (AVEO) Surprise in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 5:42PM CDT
AVEO Pharmaceuticals (AVEO) is expected to report first-quarter 2016 results on Mar 5.
ZTS: 47.55 (+0.22), OPHT: 54.64 (+0.48), AVEO: 0.94 (-0.05), NVS: 80.21 (+0.50)

AVEO Announces Filing of Provisional Patent Applications for AV-353, a Notch 3-Specific Inhibitor Antibody for PAH
BusinessWire - Mon May 02, 6:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced that it has filed provisional patent applications with the United States Patent and Trademark Office (USPTO) covering composition of matter claims for AV-353, the Company's potent inhibitory antibody specific to Notch 3. These patent applications are the second set of applications related to AV-353 and the Company's Notch 3 antibody program.
AVEO: 0.94 (-0.05)

AVEO Gives AV-203 Ex-U.S. Rights to CANbridge Life Sciences
Zacks Equity Research - Zacks Investment Research - Wed Mar 23, 3:25AM CDT
AVEO Pharmaceuticals (AVEO) struck an exclusive collaboration and license agreement granting CANbridge Life Sciences rights to AV-203 outside North America.
BIIB: 237.34 (+2.74), OPHT: 54.64 (+0.48), AVEO: 0.94 (-0.05), NVS: 80.21 (+0.50)

AVEO Q4 Loss Narrower than Expected, Tivozanib in Focus
Zacks Equity Research - Zacks Investment Research - Wed Mar 16, 9:00AM CDT
AVEO Pharmaceuticals (AVEO) reported a narrower-than-expected fourth-quarter 2015 loss of 11 cents per share.
AVEO: 0.94 (-0.05), ANIK: 50.61 (+0.34), NVS: 80.21 (+0.50)

AVEO (AVEO) Reports Narrower-than-Expected Loss in Q4
Zacks Equity Research - Zacks Investment Research - Tue Mar 15, 8:21AM CDT
AVEO Pharmaceuticals (AVEO) reported narrower-than-expected fourth quarter loss of 11 cents per share.
AVEO: 0.94 (-0.05)

AVEO Oncology Reports Full Year 2015 Financial Results and Provides Business Update
BusinessWire - Tue Mar 15, 6:30AM CDT
AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2015 and provided a business update.
AVEO: 0.94 (-0.05)

AVEO to Present at the 28th Annual ROTH Conference
BusinessWire - Wed Mar 09, 6:00AM CST
AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at the 28th Annual ROTH Conference on Wednesday, March 16, 2016, at 9:00 a.m. Pacific Time. The conference is being held at The Ritz Carlton Hotel in Dana Point, CA.
AVEO: 0.94 (-0.05)

Endometrial Cancer Pipeline Market Research H2 2015 Report
PR Newswire - Wed Mar 02, 8:00PM CST
A market research report titled "Endometrial Cancer - Pipeline Review, H2 2015" provides an overview of the Endometrial Cancer's therapeutic pipeline and enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
INCY: 78.98 (+0.48), IMGN: 3.30 (+0.05), ARQL: 1.91 (+0.02), LLY: 73.33 (+0.26), GSK: 42.24 (+0.48), ONTY: 1.21 (+0.02), MDVN: 59.15 (+0.26), MRK: 57.33 (+0.29), AZN: 29.03 (+0.33), AVEO: 0.94 (-0.05), GALE: 2.26 (-0.01), PBYI: 31.57 (+0.04), NVS: 80.21 (+0.50), KPTI: 7.96 (+0.28), XLRN: 33.70 (+0.14), EXEL: 7.80 (+0.06)

Will AVEO (AVEO) Surprise Estimates in Q4 Earnings Again?
Zacks Equity Research - Zacks Investment Research - Wed Mar 02, 3:45PM CST
AVEO Pharmaceuticals (AVEO), which is expected to report fourth-quarter 2015 results on Mar 4, had recorded a positive earnings surprise of 200% last quarter.
BDSI: 2.35 (+0.02), OPHT: 54.64 (+0.48), AVEO: 0.94 (-0.05), NVS: 80.21 (+0.50)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 530

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 270

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 5

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 398

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 348

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 607

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading

Top 5 Most Recently Viewed Articles

International Isotopes Enhances Growth with New Facilities

Updated Category News Views 139

International Isotopes Expands Its Operational Footprint International Isotopes, Inc. (OTCQB: INIS) has announced a significant expansion of its operational capabilities with a strategic land acquisition and a new facility lease agreement. This initiative is part of a broader strategy aimed at enhancing the Company's footprint in the radiopharmaceuticals sector. Strategic...

Continue Reading
Humana Achieves Top Honors in Customer Experience Again

Updated Category News Views 80

Humana Excels in Customer Experience for Four Straight Years Humana has once again secured the top position in customer experience among health insurers, according to a recent survey conducted by Forrester. This marks the fourth consecutive year that Humana has achieved this prestigious recognition, reaffirming its commitment to delivering exceptional service and care to...

Continue Reading
BrainStorm Cell Therapeutics Presents Insights into ALS Treatment

Updated Category News Views 128

BrainStorm Cell Therapeutics Webinar on ALS Treatments BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a prominent innovator in adult stem cell therapeutics for neurodegenerative diseases, will be hosting an insightful webinar on current developments in treating amyotrophic lateral sclerosis (ALS). This event is designed to provide essential updates and perspectives...

Continue Reading
Celebrating Excellence: The 2024 Employer Branding Awards Unveiled

Updated Category News Views 235

Overview of the Employer Branding Creativity Awards The "2024 Employer Branding Creativity Awards" organized by the Employer Branding Institute, recognized 75 exemplary companies for their innovative contributions to employer branding. Sponsored by Jaguar Land Rover China, this prestigious event not only celebrates creativity but also demonstrates the rising influence of...

Continue Reading
Battery Recycling Market Expected to Hit $77.1 Billion by 2034

Updated Category News Views 210

Battery Recycling Market Overview The battery recycling market is gaining remarkable traction worldwide, projected to soar to $77.1 billion by 2034. This forecast represents a significant growth trajectory from a valuation of $26.9 billion in 2024, indicating a compound annual growth rate (CAGR) of 11.2% from 2025 to 2034. Impact of Government Regulations Government...

Continue Reading